Long-term outcomes following infection of cardiac implantable electronic devices: a prospective matched cohort study

Objective To assess long-term outcomes and predictors of mortality in patients treated according to current recommendations for cardiac implantable electronic device (CIED) infection. Design Two-group matched cohort study. Setting Tertiary-care institution. Patients Consecutive patients admitted for CIED infection between 2004 and 2008 were prospectively enrolled. Study subjects were matched to a cohort of uninfected CIED patients by age, sex and type of device. Interventions In all infected patients, the therapeutic approach consisted of complete hardware removal whenever possible, antimicrobial therapy, and implantation of a new device, if indicated. Patients were systematically followed, with standardised outcomes assessment. Main outcome measures All-cause mortality and predictors of long-term mortality. Results 197 patients were included and matched 1:1 to controls. Pocket infections were present in 41.1% and definite or suspected infective endocarditis in 58.9%. Total or subtotal hardware removal was achieved in 98.5% of cases. Median follow up was 25 months (12–70). Mortality rates in the study group and controls were 14.3% vs 11.0% (NS) at 1 year and 35.4% vs 27.0% (p=NS) at 5 years. Independent predictors of long-term mortality were older age (HR=1.09, p<0.001), cardiac resynchronisation therapy (HR=3.70, p=0.001), thrombocytopenia (HR=5.10, p=0.003) and renal insufficiency (HR=2.66, p=0.006). In patients with reimplanted devices, epicardial right ventricular pacemakers were associated with higher mortality (HR=2.85, p=0.034). Conclusion In patients with CIED infection managed by recommended therapy, long-term mortality rates are similar to comparable controls. Independent predictors include patient and disease-related factors, in addition to implantation of right ventricular epicardial pacemakers.

[1]  D Lacroix,et al.  Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. , 1997, Circulation.

[2]  B. Wilkoff,et al.  Cardiac implantable electronic device infections: presentation, management, and patient outcomes. , 2010, Heart rhythm.

[3]  R. Friedman,et al.  Recommendations for Extraction of Chronically Implanted Transvenous Pacing and Defibrillator Leads: Indications, Facilities, Training , 2000, Pacing and clinical electrophysiology : PACE.

[4]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[5]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Circulation.

[6]  M. Sweeney,et al.  Heart Failure During Cardiac Pacing , 2006, Circulation.

[7]  Jeroen J. Bax,et al.  The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy. , 2009, Journal of the American College of Cardiology.

[8]  Bruno Hoen,et al.  Staphylococcus aureus endocarditis: a consequence of medical progress. , 2005, JAMA.

[9]  É. Marijon,et al.  Safety of Deferring the Reimplantation of Pacing Systems After Their Removal for Infectious Complications in Selected Patients: A 1‐Year Follow‐Up Study , 2010, Journal of cardiovascular electrophysiology.

[10]  David L Hayes,et al.  Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. , 2007, Archives of internal medicine.

[11]  Maria Grazia Bongiorni,et al.  Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). , 2009, Heart rhythm.

[12]  GUIDELINES ON THE PREVENTION, DIAGNOSIS, AND TREATMENT OF INFECTIVE ENDOCARDITIS (NEW VERSION 2009) , 2010 .

[13]  J. Valle,et al.  Risk Factors for Mortality in Patients With Cardiac Device-Related Infection , 2009, Circulation. Arrhythmia and electrophysiology.

[14]  David Longworth,et al.  Diagnosis and Management of Infections Involving Implantable Electrophysiologic Cardiac Devices , 2000, Annals of Internal Medicine.

[15]  M. Messier,et al.  Prevalence and risk factors related to infections of cardiac resynchronization therapy devices. , 2010, European heart journal.

[16]  Gilbert Habib,et al.  Risk of Embolism and Death in Infective Endocarditis: Prognostic Value of Echocardiography: A Prospective Multicenter Study , 2005, Circulation.

[17]  Patricia Muñoz,et al.  Contemporary clinical profile and outcome of prosthetic valve endocarditis. , 2007, JAMA.

[18]  L. Kritharides,et al.  Thrombocytopenia and mortality in infective endocarditis. , 2008, Journal of the American College of Cardiology.

[19]  A. Pavie,et al.  Pacemaker infective endocarditis. , 1998, The American journal of cardiology.

[20]  Manfred Zehender,et al.  Long-term survival after pacemaker implantation. Prognostic importance of gender and baseline patient characteristics. , 2004, European heart journal.

[21]  D. Raoult,et al.  Diagnosis of cardiac device-related infective endocarditis after device removal. , 2010, JACC. Cardiovascular imaging.

[22]  U. Kappert,et al.  Percutaneous Lead Implantation Connected to an External Device in Stimulation‐Dependent Patients with Systemic Infection—A Prospective and Controlled Study , 2006, Pacing and clinical electrophysiology : PACE.

[23]  D. Durack,et al.  New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. , 1994, The American journal of medicine.

[24]  David L Hayes,et al.  Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. , 2008, Mayo Clinic proceedings.

[25]  David L Hayes,et al.  Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. , 2007, Journal of the American College of Cardiology.

[26]  A. Moss,et al.  Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator: An Extended 8-Year Follow-Up Study of the Multicenter Automatic Defibrillator Implantation Trial II , 2010, Circulation.

[27]  R. Nishimura,et al.  ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angio , 2008, Journal of the American College of Cardiology.

[28]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[29]  Walter R Wilson,et al.  Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. , 2010, Circulation.

[30]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Journal of the American College of Cardiology.

[31]  S. Saba,et al.  Continued Rise in Rates of Cardiovascular Implantable Electronic Device Infections in the United States: Temporal Trends and Causative Insights , 2010, Pacing and clinical electrophysiology : PACE.

[32]  J. Deharo,et al.  Incidence, risk factors, and outcome of traumatic tricuspid regurgitation after percutaneous ventricular lead removal. , 2009, Journal of the American College of Cardiology.